Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.